Myelin oligodendrocyte glycoprotein (MOG)–IgG has emerged as a reproducible marker for patients with optic neuritis or those with an aquaporin-4 (AQP4)–IgG–negative neuromyelitis optica spectrum disorders (NMOSD) phenotype.1 MOG-IgG optic neuritis tends to have a more favourable prognosis compared with those with AQP4-IgG, but poor visual outcomes may occur in a minority of patients with this condition.2 Certain magnetic resonance imaging (MRI) features may suggest MOG-IgG disease—especially perineural enhancement and longitudinal involvement.
Myelin oligodendrocyte glycoprotein (MOG)–IgG has emerged as a reproducible marker for patients with optic neuritis or those with an aquaporin-4 (AQP4)–IgG–negative neuromyelitis optica spectrum disorders (NMOSD) phenotype.1 MOG-IgG optic neuritis tends to have a more favourable prognosis compared with those with AQP4-IgG, but poor visual outcomes may occur in a minority of patients with this condition.2 Certain magnetic resonance imaging (MRI) features may suggest MOG-IgG disease—especially perineural enhancement and longitudinal involvement.